Prenetics Global (NASDAQ:PRE) Shares Down 1.6% – Here’s Why

Prenetics Global Limited (NASDAQ:PRE)’s stock price was down 1.6% during trading on Friday . The stock traded as low as $5.70 and last traded at $5.70. Approximately 1,032 shares changed hands during trading, a decline of 98% from the average daily volume of 48,158 shares. The stock had previously closed at $5.79.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $9.00 target price on shares of Prenetics Global in a report on Wednesday, December 4th.

Prenetics Global Price Performance

The business’s fifty day simple moving average is $4.88 and its 200 day simple moving average is $5.12. The firm has a market capitalization of $52.08 million, a price-to-earnings ratio of -1.43 and a beta of -0.18.

Prenetics Global (NASDAQ:PRE) last issued its earnings results on Monday, October 7th. The company reported ($0.88) EPS for the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. The firm had revenue of $5.94 million during the quarter. Equities research analysts expect that Prenetics Global Limited will post -3.3 earnings per share for the current fiscal year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.